Supplemental Material Supplemental Methods

Data sources and availability
The low-pass whole-genome sequencing (WGS) dataset (phase1) and the genotyping dataset (phase 2) of the MHI Biobank have been previously described 1, 2 . Case status for coronary artery disease (CAD) prevalence was defined as having a myocardial infarction (MI) or coronary artery interventions (coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI)) before the first visit. Controls were selected to be free of MI, PCI, CABG, transient ischemic attack or stroke, peripheral vascular disease, congestive heart failure, and angina. We used the same clinical definitions to identify incident and recurrent CAD events in the MHI Biobank: participants who had a first-ever CAD event between baseline and follow-up were considered incident cases and participants who had at least a second CAD event during the same period were considered recurrent CAD cases. Average follow-up time was 4.2 years for phase 1 and 3.6 years for phase 2. We used GenomeStrip (v.2.0) with default parameters on the MHI Biobank phase 1 WGS data to identify participants who carry the known French-Canadian founder LDLR deletion 3 . We excluded the 14 individuals who carry the LDLR delta > 15 kb deletion from all subsequent PRS analyses. CARTaGENE (www.cartagene.qc.ca) is a population-based cohort of Quebec that includes individuals aged between 40 and 69 years 4 . A subset of this cohort totaling 5762 samples were genotyped on the Illumina Infinium Global Screening Array (GSA). We used PLINK (version 1.9, https://www.cog-genomics.org/plink/1.9/) to apply the following quality-control filters: we excluded samples and variants with >5% missingness, variants out of Hardy-Weinberg Equilibrium (p-value<1x10 -6 ), A/T and G/C variants, and variants with a minor allele frequency (MAF) <1%. Following these qualitycontrol steps, we phased genotypes with ShapeIT v2.r790 and imputed missing genotypes on the Michigan Imputation Server (version 1.30.4) using the Haplotype Reference Consortium panel (Version r1.1 2016) 5, 6 . Case-control status for CAD in CARTaGENE was defined using the same criteria than for the MHI Biobank (see above). Principal components for all three cohorts were calculated in PLINK using the pca function.
Polygenic risk scores
The models for the two polygenic risk scores (PRS) (GPS CAD and metaGRS CAD ) used in this study are available online (see Web links below) 7, 8 . Genetic risk scores for all models were generated with PLINK (version 1.9) and the --score function to calculate the sum of the product of the dosage of effect alleles per variant weighted by the CAD effect size 9 . We excluded variants with low imputation quality score (rsq <0.3). PRS were Z-score normalized and centered (mean=0, standard deviation=1) per dataset to facilitate interpretation of odds ratios. Detailed numbers for missing variants from all models can be found in Table S1 . 10 We performed all statistical analysis in R (version 3.5.0) . In the MHI Biobank datasets, we tested by logistic regression the association between CAD case-control status and PRS Z-scores correcting for age, sex, and the first four principal components. In the MHI Biobank phase 1 and 2 data, we also corrected for statin use when appropriate. For the CARTaGENE data, we used a similar logistic regression model, correcting for age, sex, the first four principal components, and recruitment center. We calculated odds ratios per standard deviation of the GPS CAD or metaGRS CAD PRS, and considered p-value < 0.05 as significant. P-values were not corrected for multiple testing. We calculated the area under the curve (AUC) using the pROC package in R
Statistical analysis
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. Meta-analysis was performed with the R metafor package using the coefficients and standard errors (SE) from the individual regression models with a fixed effect model fitted with the "FE" method 12 . We tested the association between LDLcholesterol levels and the LDLR deletion in RVTest using the score test function 13 . For these analyses, we increased the LDL-C levels of dyslipidemic participants by 30% to account for the effect of statins.
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Supplemental Tables   Table S1 . Variants available from each cohort to calculate the two coronary artery disease polygenic risk scores. PRS = polygenic risk score used, n variants model = Total variants included in the model, variants scored = Percentage of variants from model that were present in data and used for scoring, variants missing = percentage of variants missing from scoring, rsq < 0.3 = number of variants that were excluded due to low imputation quality, other ALT = number of variants excluded due to different alternative allele than in reference model, missing = number of PRS model variants absent in dataset. N.A. = not applicable. 
